John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 03, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 3:45pm ET in New York.
A live audio webcast of the presentation can be accessible by visiting ir.agtc.com/events.cfm. A replay will be available on the company’s website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.
CONTACT: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 [email protected] or [email protected] Corporate Contacts: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 [email protected] Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
